The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: Iodine-123-iodobenzamide single photon emission computed tomography study


Por: Corripio, I, Ferreira, A, Portella, MJ, Perez, V, Escarti, MJ, Camacho, MD, Sauras, RB, Alonso, A, Grasa, EM, Carrio, I, Catafau, AM, Alvarez, E

Publicada: 30 ene 2012
Resumen:
Levels above 75% of striatal dopamine 2 receptor occupancy (D2RO) have been associated with extrapyramidal symptoms (EPS). The aim of the present study is to investigate the relationship between D2RO and EPS in a sample of psychotic patients in current treatment with both typical and atypical antipsychotics. Brain iodine-123-iodobenzamide single photon emission computed tomography (I-123-IBZM SPECT) was performed in 81 patients taking stable doses of haloperidol, risperidone, olanzapine, quetiapine, clozapine or ziprasidone. First, the degree of D2RO and Positive and Negative Syndrome Scale (PANSS) scores was compared between the group of patients who presented EPS and the group free of EPS. Afterwards, these variables were compared among the different antipsychotic medications. The group with EPS presented means of D2RO significantly higher than the group free of EPS. Significant differences in D2RO were found in clozapine, quetiapine and ziprasidone groups compared with the haloperidol group. No differences were observed between either olanzapine or risperidone and haloperidol. No quetiapine- or clozapine-treated patients developed EPS. Haloperidol and risperidone demonstrated a relationship between striatal D2RO and EPS. The findings suggest that higher D2RO is related to appearance of EPS. Occupancy in the group with EPS was in agreement with previous studies that suggested a high degree of D2RO is necessary for the occurrence of EPS. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

Filiaciones:
Corripio, I:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

Ferreira, A:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

 Mental Hlth Ctr Horta Guinardo, Barcelona 08024, Spain

Portella, MJ:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

Perez, V:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

Escarti, MJ:
 Hosp Clin Univ Valencia, Dept Psychiat, Ctr Invest Biomed Red Salud Mental, CIBERSAM, Valencia 46010, Spain

Camacho, MD:
 Hosp Santa Creu & Sant Pau, Dept Nucl Med, Barcelona 08025, Spain

Sauras, RB:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

Alonso, A:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

Grasa, EM:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain

Carrio, I:
 Hosp Santa Creu & Sant Pau, Dept Nucl Med, Barcelona 08025, Spain

Catafau, AM:
 Barcelona Imaging Grp SL, Barcelona 08193, Spain

Alvarez, E:
 UAB, Hosp Santa Creu & St Pau, CIBERSAM, Ctr Invest Biomed Red Salud Mental,Dept Psychiat, Barcelona 08025, Spain
ISSN: 09254927





PSYCHIATRY RESEARCH-NEUROIMAGING
Editorial
ELSEVIER IRELAND LTD, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND, Países Bajos
Tipo de documento: Article
Volumen: 201 Número: 1
Páginas: 73-77
WOS Id: 000301805400010
ID de PubMed: 22281201

MÉTRICAS